Research Analysts’ Recent Ratings Changes for ResMed (RMD)

Several brokerages have updated their recommendations and price targets on shares of ResMed (NYSE: RMD) in the last few weeks:

• 11/2/2026 – ResMed was downgraded by Canaccord Genuity Group from “buy” to “hold”.
• 10/30/2026 – ResMed had its “hold” rating reaffirmed by Needham & Company LLC.
• 10/30/2026 – ResMed was given a new $270.00 price target by Mizuho.
• 10/30/2026 – ResMed had its price target raised by Citigroup from $240.00 to $270.00. They now have a “neutral” rating on the stock.
• 10/30/2026 – ResMed had its price target raised by Wells Fargo & Company from $215.00 to $250.00. They now have an “equal weight” rating on the stock.
• 10/30/2026 – ResMed had its price target raised by Royal Bank Of Canada from $262.00 to $288.00. They now have an “outperform” rating on the stock.
• 10/30/2026 – ResMed had its price target raised by KeyCorp from $267.00 to $277.00. They now have an “overweight” rating on the stock.
• 10/13/2026 – ResMed was given a new $240.00 price target by Mizuho.
• 10/8/2026 – ResMed was upgraded by Weiss Ratings from “hold (c)” to “hold (c+)”.
• 9/15/2026 – ResMed was upgraded by Royal Bank Of Canada from “sector perform” to “outperform”. They now have a $262.00 price target on the stock, up from $244.00.
• 9/10/2026 – ResMed had its “neutral” rating reaffirmed by Citigroup.

ResMed Price Performance

Shares of RMD stock opened at $240.43 on Thursday. ResMed Inc. has a twelve month low of $180.26 and a twelve month high of $277.67. The company has a current ratio of 2.65, a quick ratio of 1.88 and a debt-to-equity ratio of 0.04. The stock has a fifty day simple moving average of $231.86 and a two-hundred day simple moving average of $225.06. The stock has a market capitalization of $33.82 billion, a price-to-earnings ratio of 21.90, a P/E/G ratio of 1.38 and a beta of 0.77.

ResMed (NYSE:RMD) last announced its quarterly earnings results on Thursday, October 29th. The medical equipment provider reported $2.91 EPS for the quarter, beating the consensus estimate of $2.67 by $0.24. The firm had revenue of $1.41 billion for the quarter, compared to analyst estimates of $1.39 billion. ResMed had a return on equity of 26.42% and a net margin of 27.79%. The business’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter last year, the firm posted $2.55 earnings per share. On average, analysts predict that ResMed Inc. will post 12.14 EPS for the current fiscal year.

ResMed Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 17th. Stockholders of record on Thursday, November 12th will be issued a dividend of $0.66 per share. This represents a $2.64 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Thursday, November 12th. ResMed’s dividend payout ratio is currently 24.04%.

Insider Transactions at ResMed

In other ResMed news, CEO Michael Farrell sold 4,991 shares of the firm’s stock in a transaction dated Wednesday, October 7th. The stock was sold at an average price of $226.33, for a total value of $1,129,613.03. Following the completion of the sale, the chief executive officer owned 479,803 shares of the company’s stock, valued at approximately $108,593,812.99. This trade represents a 1.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Michael Rider sold 400 shares of the business’s stock in a transaction that occurred on Friday, October 23rd. The stock was sold at an average price of $255.00, for a total transaction of $102,000.00. Following the sale, the general counsel directly owned 12,318 shares in the company, valued at approximately $3,141,090. This represents a 3.15% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 16,343 shares of company stock valued at $3,596,098 in the last quarter. 0.58% of the stock is currently owned by corporate insiders.

ResMed Inc is a medical equipment and software company that develops solutions for sleep-disordered breathing, respiratory conditions and other chronic diseases. The company is best known for its positive airway pressure (PAP) devices used to treat obstructive sleep apnea, along with masks, accessories and related patient support services.

ResMed also provides cloud-connected health technology, including remote-monitoring platforms and software used by healthcare providers, medical equipment suppliers and care organizations.